Trial
NCT02214628
Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF BB) Regimen Administered in Combination With Anti-VEGF Therapy to Study Sub-Retinal Fibrosis in Neovascular AMD
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Ophthotech Corporation
Collaborators
—
Condition
Age-related Macular Degeneration
Intervention
Fovista® (anti-PDGF BB) plus anti-VEGF
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-02-23